Our Blog

Will Rhofade be the product that Mirvaso wanted to be?

Back

29/03/17

The facial redness of rosacea is a huge annoyance to many thousands of patients. Medications that activate alpha adrenoreceptors cause blood vessels to shrink down temporarily and reduce redness.

The facial redness of rosacea is a huge annoyance to many thousands of patients. Medications that activate alpha adrenoreceptors cause blood vessels to shrink down temporarily and reduce redness. Mirvaso gel ( brimonidine) was the first product licensed for rosacea to target these receptors. Initial results were good but then many patients went on to develop rebound flushing and this side effect has prevented the wide spread use that was predicted. Now, a new product has been approved for use in rosacea. Rhofade ( oxymetalazine) targets only the alpha 1a receptors . Early reports suggest much less rebound erythema. If this is true in clinical practice this could be the cream that many rosacea patients have been waiting for.